Asuragen enriches the oncology portfolio with the CE mark and the launch of the QuantideX ® NGS DNA Hotspot 21 Kit

Thursday, September 06, 2018

Asuragen, Inc. , a molecular diagnostics company specializing in high-quality and easy-to-use products for conducting complex tests in the field of genetics and oncology, today announced the achievement of the CE mark and the launch of the QuantideX ® KitNGS DNA Hotspot 21, a next-generation sequencing tool (NGS) specifically designed for the detection of clinically relevant variants in many types of tumors, including non-small cell lung cancer, colorectal cancer and melanoma . By screening the most commonly observed variants with a simple procedure, the kit overcomes the current clinical and laboratory challenges that characterize NGS tests, including long response times, high complexity of analyzes and laborious interpretation of data. The test represents an evolution of the existing QuantideX ® Kit NGS Pan Cancer, further streamlining the analysis procedure and harmonizing the execution conditions to allow parallel processing of samples with the QuantideX ® NGS RNA Lung Cancer Kit.

The QuantideX NGS DNA Hotspot 21 Kit, featuring the exclusive NGS-in-a-Box ™ end-to-end design, developed by Asuragen under current good manufacturing practices (current Good Manufacturing Practice, cGMP), provides reagents necessary for the preparation of ready sequencing libraries in a single day, as well as analysis tools for rapid standardization of results after sequencing. The bioinformatics software owned by Sample-Aware ™ evaluates if the amount of amplifiable DNA present is sufficient, giving an answer to the common concerns regarding quality and quantity of the samples. Like the QuantideX NGS RNA Lung Cancer Kit, this assay is designed for use on the widely distributed Illumina MiSeq platform, which further facilitates its adoption and implementation.

"The launch of the QuantideX NGS DNA Hotspot 21 Kit further reiterates Asuragen's commitment to providing simple and rational laboratory molecular analysis products, even in the case of complex technologies such as next-generation sequencing," said Dr. prof. Matthew McManus, president and CEO of Asuragen. "Like all our products, this kit reduces the complexity of laboratory activities, optimizing both the procedures and the quality of the results, all fundamental aspects to offer patients the best quality care".

About Asuragen

Asuragen is a manufacturer of molecular diagnostic devices that can revolutionize the way patients are treated in the genetic and oncological field. The quality, simplicity and sensitivity of its products allow everyone to make use of precision medicine. Asuragen's diagnostic systems, made up of patented chemical software and technologies, offer effective answers through the use of large-scale instrumental platforms. Easy to use, they allow greater satisfaction of patients' needs. Asuragen is a forge of products that can quickly and efficiently meet current and emerging clinical needs, including oncology monitoring and diagnostics. aging and reproductive health, equipping the laboratories with the best diagnostic tests that can be found in circulation for the whole life of the patients. For more information visitwww.asuragen.com .

The original text of this announcement, written in the source language, is the official version that is authentic. Translations are offered solely for the convenience of the reader and must refer to the original text, which is the only legally valid one.

Contacts
Asuragen, Inc.
Lynne Hohlfeld, 512-681-5200
Senior Vice President Corporate Development and Financial Manager
lhohlfeld@asuragen.com